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Patients on hemodialysis often have gastrointestinal
complications; however, it is unclear if Helicobacter pylori
infection is present in these patients. Here we determined
the prevalence of H. pylori infection in 539 Japanese
hemodialysis patients by measuring serum anti-H. pylori IgG
antibodies. Endoscopy was performed on 299 of these
patients and the results were compared to 400 patients with
normal renal function who had also undergone endoscopy
and sero-testing. A second cohort of 478 dialysis patients,
within the original group, was checked serologically for
H. pylori infection three times over a four-year observation
period. The prevalence of infection in these patients was
significantly lower than in those patients with normal renal
function, irrespective of the clinical outcomes. The
prevalence of H. pylori infection significantly decreased as the
duration of dialysis increased, particularly within the first four
years following initiation of dialysis. About one-third of
patients on dialysis for less than four years became
serologically negative for H. pylori infection within this
observation period. Our study suggests that although long-
term dialysis patients have low prevalence of H. pylori, they
still have significant gastroduodenal diseases, such as peptic
ulcers, that require endoscopic follow-up.
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Helicobacter pylori (H. pylori) is a spiral-shaped Gram-
negative flagellate bacterium. Chronic H. pylori infection has
close associations with gastrointestinal diseases, such as
peptic ulcer (PU), gastric hyperplastic polyps, gastric
adenoma, gastric cancer, and gastric mucosa-associated
lymphoid tissue lymphoma.1–3 Recently, increased evidence
suggests that the development of some extragastrointestinal
disorders including idiopathic thrombocytopenic purpura,
chronic idiopathic urticaria, and iron deficiency anemia are
also related with H. pylori infection of gastric mucosa.4–6 In
these infected patients, the eradication of H. pylori is
recommended as the first-line therapy for the prevention
and cure of gastroduodenal diseases.1,7 Although there is no
significant evidence that H. pylori infection is directly
associated with progression of renal dysfunction, patients
receiving chronic hemodialysis and continuous ambulatory
peritoneal dialysis (CAPD) often incur gastrointestinal
troubles over their long treatment period.8–17
Patients with chronic renal failure (CRF) present with
various clinical symptoms, including nausea, dyspepsia,
appetite loss, epigastric discomfort, and heartburn, as well
as histological, physiological, and functional disorders of the
gastrointestinal system.18,19 These symptoms not only
decrease the quality of life of patients, but also may affect
their nutrition status, thus contributing to the development
of malnutrition, which is a potent predictor of morbidity and
mortality in patients with CRF. Moreover, 25–75% of patients
with CRF undergoing dialysis suffer from a number of
gastrointestinal lesions and their complications (for example,
gastric erosions, PUs, angiodysplasia, and gastrointestinal
bleeding).8–17,20
H. pylori infection is crucial in many gastrointestinal
conditions not only in individuals with normal renal
function, but also in CRF patients receiving chronic dialysis,
CAPD, and kidney transplant. Recently, although associa-
tions between patients with CRF and the prevalence of
H. pylori infection have been reported,9–14,21–59 their results
are still controversial, probably due to small number of
studies and short duration periods. Only four previous
studies examined more than 200 patients (maximum of 322
patients20), and no previous studies examined patients with
mean dialysis duration periods of 4100 months. In addition,
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only few reports evaluated the relationship between H. pylori
infection and dialysis treatment duration.41,49 Therefore, we
aimed to clarify the prevalence of H. pylori infection in more
than 500 patients receiving dialysis with a mean duration
period of more than 8 years. Moreover, we first performed a
follow-up survey to assess H. pylori infection in the same
patient cohort receiving dialysis for 4 years.
RESULTS
Patients
A total of 539 patients receiving dialysis at Tojinkai Hospital,
Kyoto, Japan during April 1997 were enrolled in this study.
A total of 400 patients with normal renal function who
underwent endoscopy at the University Hospital of Kyoto
Prefectural University of Medicine, Kyoto, Japan between
January 1996 and April 1997 were also enrolled in this
study. Among them 121 patients visited the hospital
for annual health check irrespective of gastrointestinal
symptoms and remaining patients for investigation of
gastrointestinal symptoms. All patients were determined
H. pylori status by serological test using anti-H. pylori
immunoglobulin G (IgG) antibody at the beginning of this
study in 1997.
Accuracy of serological test for patient receiving dialysis
treatment
The detection of H. pylori status by anti-H. pylori IgG
antibody in patients receiving dialysis treatment might be
influenced by the impaired immune system, and might be
judged as false-negative cases. To check the accuracy of this
serological test, we performed 13C-urea breath test as well as
two invasive tests using biopsy specimens obtained during
endoscopy (H. pylori culture and rapid urease test) for
randomly selected 70 patients who had either positive or
negative serological test. When at least one of alternative tests
yielded positive results, we judged the patients as H. pylori
positive and compared with the serological test. The
specificity, sensitivity, positive predictive value, negative
predictive value, and accuracy of serological test were 94.1,
97.2, 97.0, 94.6, and 95.7%, respectively, confirming that this
serological test was reliable and accurate even for patients
receiving dialysis treatment.
Prevalence of H. pylori infection in patients receiving dialysis
at the beginning of the study
Demographic and clinical characteristics of patients enrolled
at the beginning of the study (1997) are summarized in
Table 1. The basement diseases in chronic dialysis patients
were chronic glomerulonephritis (CGN) including IgA
nephropathy, membranous nephropathy, minimal change,
and antineutrophil cytoplasmic antibody-related nephritis
(n¼ 388), diabetes (n¼ 103), and others including lupus
nephritis, polycystic kidney, chronic pyelonephritis, and
nephrosclerosis (n¼ 48). There were no significant differ-
ences in age, sex, and symptom scores among different
basement diseases of dialysis (Table 1). Gastrointestinal
symptoms also had no association with H. pylori status and
dialysis duration (data not shown). The prevalence of
H. pylori infection and H. pylori IgG levels in patients with
diabetic nephropathy was significantly higher than in the
CGN group (P¼ 0.01 for each) (Table 1). In addition, the
treatment period in patients with diabetic nephropathy was
4.9±0.4 years, which was significantly shorter than those
with the CGN group (9.2±0.4 years, Po0.01).
The prevalence of H. pylori infection in patients receiving
dialysis (mean duration of 8.4±0.3 years) was 48.6% (95%
confidence interval (CI): 44.3–52.9%, 262 of 539), which was
significantly lower than in all patients with normal renal
function (78.5%, 95% CI: 74.1–82.4%, 314 of 400, Po0.001)
as well as patients with normal renal function who visited
the hospital for annual health check (69.4%, 95% CI:
60.4–77.5%, 84 of 121, P¼ 0.001) (Table 1). Importantly,
the prevalence of H. pylori infection in patients receiving
dialysis treatment for less than 1 year (74.1%, 60.3–85.0%, 40
of 54) was similar to annual health check patients with
normal renal function (P¼ 0.10). The mean duration of
dialysis treatment in H. pylori-positive patients (6.62±0.4
years) was significantly shorter than in negative patients
(9.45±0.4 years, Po0.01).
Table 1 | Patient demographics
Patients with normal renal function Dialysis patients
Annual health check Total CGN Diabetic nephritis Others Total P-value* P-value**
n 121 400 388 103 48 539
Sex (M/F) 59/62 223/117 219/169 55/48 23/25 296/241 0.50 0.84
Age 56.6±0.8 58.4±0.6 58.7±0.6 60.4±1.3 59.4±1.9 58.8±0.4 0.49 0.45
H. pylori+ (%) 84 (69.4) 314 (78.5) 179 (46.1) 62 (60.2) 21 (43.8) 262 (48.6) 0.03 o0.01
H. pylori IgG (U/ml) 22.3 (4.5–33.9) 26.4 (20.1–38.3) 8.7 (2.4–26.0) 20.2 (2.6–24.8) 8.9 (1.7–22.0) 15.1 (2.3–25.0) 0.19 o0.01
Dialysis period (year) NA NA 9.2±0.4 4.9±0.4 9.2±1.1 8.4±0.3 o0.01 —
Symptom scores (%) NT NT 1 (1–1) 1 (1–1) 1 (1–1) 1 (1–1) 0.33 —
1.4±0.7 (13.5) 1.4±0.1 (15.2) 1.1±0.1 (5.4) 1.4±0.1 (13.0)
CGN, chronic glomerulonephritis, NA, not available, NT, not tested.
Age and dialysis period are reported as mean±SD, and H. pylori IgG levels and symptom scores are presented as median (25–75% quartiles), mean±SD and percentage of
patients with symptom. Patients with normal renal function did not test the symptom scoring, but only presence/absence of symptom.
*Analyzed differences among three different basement diseases of hemodialysis. **Analyzed differences among dialysis patients and patients with normal renal function.
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Endoscopical finding in patients at the beginning of the
study
Endoscopic examination was performed in 299 patients
receiving dialysis treatment as well as all patients with normal
renal function. There were no significant differences in age, sex,
dialysis period, and H. pylori status between dialysis patients
with and without receiving endoscopy (data not shown).
Endoscopic findings were divided into five diseases: simple
gastritis or normal appearing mucosa without ulcer and
malignancy (gastritis), gastric ulcer, duodenal ulcer, gastric
cancer, and others (Table 2). Endoscopic examination of
dialysis patients revealed gastritis in 233 patients (77.8%),
gastric ulcer in 34 (11.4%), duodenal ulcer in 19 (6.4%), and
gastric cancer in 5 (1.7%) patients (Table 2). In patients with
normal renal function, only 46.8% (187 of 400) had gastritis
(Po0.01) probably due to the fact that patients with normal
renal function were selected from patients who received
endoscopy in the University Hospital where the frequency of
patients visiting the hospital only for annual health check
without symptoms was low. In fact, patients with normal renal
function for annual health check revealed gastritis in 112
patients (92.6%), gastric ulcer in 5 (4.1%), and duodenal ulcer
in 4 (3.3%) patients. As dialysis patients were not selected by
the presence of gastrointestinal symptoms, we compared data
of dialysis patients with those of only 121 patients with normal
renal function for annual health check in subsequent analyses.
Importantly, the prevalence of H. pylori infection was
significantly lower in dialysis patients than in patients with
normal renal function, irrespective of the clinical outcomes
(Table 3). For example, among patients with gastritis alone,
the prevalence of H. pylori infection was still significantly
lower in dialysis patients than in patients with normal renal
function (67.0 and 47.2%, Po0.01). In addition, impor-
tantly, approximately half of the dialysis patients with
duodenal ulcer (52.6%) were H. pylori negative although it
is the consensus that most of the duodenal ulcer patients are
infected with H. pylori (Table 3). In H. pylori-positive
patients, 26.7% (40 of 150) of dialysis patients and only
10.7% (9 of 87) of patients with normal renal function
developed severe gastroduodenal diseases (P¼ 0.01). In
addition, 15.2% (22 of 145) of H. pylori-negative patients
still developed severe gastroduodenal diseases, whereas none
of H. pylori-negative patients with normal renal function
(0 of 9) developed severe gastroduodenal diseases. Overall, we
could conclude that lower prevalence of H. pylori infection in
dialysis patients than in patients with normal renal function
was not due to different patterns of clinical outcomes.
The frequency of PU (duodenal ulcer and gastric ulcer) in
patients receiving dialysis treatment less than 10 years was
similar between H. pylori infected and uninfected patients
(23.7%, 28 of 118; 20.2%, 19 of 94). However, the frequency
in patients receiving dialysis treatment equal or more than 10
years was significantly higher in H. pylori-infected patients
(18.9%, 7 of 37) than in uninfected patients (4.0%, 2 of 50)
(P¼ 0.02). In addition, most ulcers in uninfected patients
were healing to the red scar stage, and active ulcers were rare
(data not shown).
When dialysis patients were divided into two groups based
on the presence or absence of gastroduodenal symptoms,
there were no significant differences of the prevalence of each
disease between two groups irrespective of H. pylori infection
(Table 4).
Table 2 | Endoscopic findings in dialysis patients and patients with normal renal function
Patients with normal renal function Dialysis patients
Diseases Annual health check Total CGN Diabetic nephritis Others Total
n 121 400 204 58 37 299
Gastritis 112 (92.6%)* 187 (46.8%)* 154 (75.5%) 49 (84.5%) 30 (81.1%) 233 (77.8%)
Gastric ulcer 5 (4.1%) 116 (29.0%) 24 (11.7%) 6 (10.3%) 4 (10.8%) 34 (11.4%)
Duodenal ulcer 4 (3.3%) 72 (18.0%) 15 (7.4%) 1 (1.7%) 3 (8.1%) 19 (6.4%)
Gastric cancer 0 (0.0%) 18 (4.5%) 3 (1.5%) 2 (3.4%) 0 (0.0%) 5 (1.7%)
Others 0 (0.0%) 7 (2.5%) 8 (3.9%) 0 (0.0%) 0 (0.0%) 8 (2.7%)
CGN, chronic glomerulonephritis.
Others included patients with mucosa-associated lymphoid tissue lymphoma, submucosal tumor, and post-gastrectomy.
*Po0.05 (compared the prevalence with total of dialysis patients).
Table 3 | Relationship between endoscopic findings and H. pylori infection
Patients with normal renal function Dialysis patients
Diseases Annual health check CGN Diabetic nephritis Others Total P-value
Gastritis 75/112 (67.0%) 67/154 (43.5%) 28/49 (57.1%) 15/30 (50.0%) 110/233 (47.2%) o0.001
Gastric ulcer 5/5 (100%) 18/24 (75.0%) 5/6 (83.3%) 2/4 (50.0%) 25/34 (73.5%) 0.189
Duodenal ulcer 4/4 (100%) 9/15 (60.0%) 0/1 (0%) 1/3 (33.3%) 10/19 (52.6%) 0.077
Gastric cancer 0/0 (0%) 1/3 (33.3%) 1/2 (50.0%) 0/0 (0%) 2/5 (40.0%) —
Others 0/0 (0%) 3/8 (37.5%) 0/0 (0%) 0/0 (0%) 3/8 (37.5%) —
Total 84/121 (69.4%) 98/204 (48.0%) 34/58 (58.6%) 18/37 (48.6%) 150/299 (50.2%) o0.001
CGN, chronic glomerulonephritis.
Others included patients with mucosa-associated lymphoid tissue lymphoma, submucosal tumor, and post-gastrectomy.
The data were demonstrated as number of H. pylori-positive patients per number of total patients with gastroduodenal disease (percentage of H. pylori-positive patients).
P-value analyzed the comparison with annual health check patients with normal renal function and dialysis patients.
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Follow-up studies with anti-H. pylori IgG antibodies
Of 539 dialysis patients, 46 patients in 1999 and 15 patients
in 2001 did not have the serological test due to death,
withdrawn agreement, or change of hospital. In the
remaining 478 dialysis patients, the basement diseases were
CGN (n¼ 346), diabetes (n¼ 89), and others (n¼ 43). We
only analyzed 478 dialysis patients in subsequent analyses for
comparison of three time points (1997, 1999, and 2001).
At the beginning of the study (1997), the prevalence of
H. pylori infection gradually decreased until 4 years after
starting dialysis, irrelevant of basement diseases, followed by
a plateau (Figure 1a). At follow-up survey of the same
patients at 2 (1999) and 4 years (2001) after initiation, the
prevalence of H. pylori infection in relation to dialysis
duration showed similar patterns observed in 1997 (Figure 1b).
This pattern showed that the prevalence of H. pylori infection
decreased in the first 4 years of dialysis and plateauing after 5
years of treatment. The decreased patterns of the prevalence of
H. pylori infection according to treatment period were similar
irrespective of the basement diseases (data not shown).
The prevalence of H. pylori infection in 1997, 1999, and
2001 was 51.6% (95% CI: 47.1–56.2%, 247 of 478), 42.9%
(38.4–47.5%, 205 of 478), and 38.3% (33.9–42.8%, 183 of
478), respectively, indicating that the infection rate gradually
decreased during dialysis treatment (Figure 2a). In other
words, 26.7% (21.3–32.7%, 66 of 247) of dialysis patients
naturally cured H. pylori infection during the observation
periods of 4 years, in particular diabetes patients (36.8%,
24.5–50.7%, 21 of 57) (Figure 2a; Table 5).
When dialysis patients were divided into three groups
according to treatment periods at the beginning of the study
in 1997 (0–4 5–9, and equal or more than 10 years), the
prevalence of H. pylori infection in patients receiving equal or
more than 5 years of dialysis treatment showed that the
patients did not naturally cure H. pylori infection (Figure 2b).
A total of 36.2% (28.3–46.5%, 42 of 116) of patients receiving
0–4 years of dialysis treatment in 1997 naturally cured
H. pylori infection during 4 years of observation (Figure 2b).
In agreement with the prevalence of H. pylori infection,
anti-H. pylori IgG antibody levels in 1997 (20.0 U/ml, 25–75%
quartiles: 5.4–25.2) were significantly decreased during 2 and
4 years of observation in 1999 (12.3, 2.3–26.5, Po0.001) and
in 2001 (11.2, 2.2–26.4, Po0.001; Figure 3a). Anti-H. pylori
IgG antibody levels in patients receiving 0–4 years of dialysis
treatment in 1997 (21.0, 5.8–34.3) was also significantly
decreased in 1999 (16.3, 5.4–26.7, Po0.001) and in 2001
(15.4, 4.5–26.5, Po0.001; Figure 3b). In contrast, anti-H.
pylori IgG antibody levels in patients receiving equal or more
than 5 years of dialysis treatment in 1997 were unchanged
during 2 and 4 years of observation (data not shown).
DISCUSSION
The prevalence of H. pylori infection in patients receiving
CAPD, chronic dialysis, or kidney transplant was reported to
be equal or lower compared to subjects with normal renal
function in various populations.9–13,21–59 Patients receiving
dialysis had significantly lower prevalence of H. pylori
Table 4 | Gastroduodenal symptoms in relation to endoscopic findings and H. pylori infection in dialysis patients
Patients with symptoms Patients without symptoms
H. pylori positive,
% (n=36)
H. pylori negative,
% (n=34)
Total,
% (n=70)
H. pylori positive,
% (n=226)
H. pylori negative,
% (n=243)
Total,
% (n=469)
Gastritis 74 87 80 61 83 72
Gastric ulcer 18 4 12 22 11 17
Duodenal ulcer 6 8 7 11 6 8
Gastric cancer 0 0 0 6 0 3
Others 2 1 1 0 0 0
Others included patients with mucosa-associated lymphoid tissue lymphoma, submucosal tumor, and post-gastrectomy.
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Figure 1 | Prevalence of H. pylori infection. (a) Within the first 4
years of treatment, the infection rate was decreased irrelevant of
basement membrane diseases causing chronic renal failure. The
decreased patterns of the prevalence of H. pylori infection
according to treatment period were similar irrespective of the
basement diseases. Prevalence of H. pylori infection in different
treatment periods: 1997, 1999, and 2001 in 478 patients. (b)
Infection rates of H. pylori in 1999 and 2001 were similar to those
observed in 1997 among patients and different treatment periods.
*Po0.05 (vs patients with treatment period of less than 1 year).
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infection in five studies,22,27,28,40,49 whereas only one study
reported that dialysis patients had significantly higher
infection rates.14 In the present study, we investigated the
largest number of dialysis patients with a variety of treatment
periods, and found that the prevalence of H. pylori infection
in dialysis patients with CRF was significantly lower than in
patients with normal renal function. The infection rate
gradually decreased with increased dialysis treatment periods.
By the 4-year follow-up period, we demonstrated that
H. pylori infection decreased in dialysis patients among
different treatment periods, and the decrease was observed
only in patients receiving dialysis for equal or less than 4 years.
Surprisingly, more than one-third (36.2%) of these patients
receiving equal or less than 4 years of dialysis treatment had
naturally cured H. pylori infection without eradication
therapies with proton pump inhibitors and antibiotics.
In Japan, renal transplantation is not well established
compared to Europe and the United States. Therefore,
patients receiving dialysis for a prolonged period (more than
10 years) are not rare. Only a few previous reports have
evaluated the relationship between H. pylori infection and
dialysis treatment period,41,49 and those reports demonstrate
that the mean dialysis duration in H. pylori-positive patients
was significantly shorter than in uninfected patients, as
confirmed in this study. Nakajima et al.49 reported that the
prevalence of H. pylori infection markedly decreased when
the treatment duration was 2 years or more. However, in all
these previous studies, only one time point was observed,
making it impossible to confirm whether the same patients
naturally cured the infection after the dialysis. Although 37
(83.7%) of 43 previous reports had no significant differences
in the prevalence of H. pylori infection among CRF patients
and individuals with normal renal function, most of those
previous reports enrolled less than 100 dialysis patients with
an observation period of less than 1 year.9–14,21–59 A short
dialysis treatment window might not reveal important
findings, such as the observed decreased incidence of
H. pylori within the first 4 years.
We performed a meta-analysis of previous report
data9–14,21–59 and data in this study to offset type 2 errors
in determining prevalence of H. pylori infection. The
prevalence of H. pylori infection in patients with renal
dysfunction receiving chronic dialysis and CAPD was 43.4%
(95% CI: 41.6–45.2%, 1284 of 2962) and 34.8% (29.6–40.2%,
113 of 325), respectively. The prevalence in overall patients
with renal dysfunction was 41.8% (40.3–43.3%), 1742 of
4171), which was significantly lower than in the individuals
with normal renal function both with and without gastro-
intestinal symptoms (48.9%, 47.0–50.8%, 1284 of 2622,
Po0.001). Although the sample size of patients receiving
CAPD and kidney transplant was small, we concluded that
patients with renal dysfunction have a low prevalence of
H. pylori infection.
There are at least three explanations as to why dialysis
patients have low prevalence of H. pylori infection: (1) blood
urea levels as well as urea nitrogen levels in gastric secretions
are higher in dialysis patients than in patients with normal
renal function, and high urea levels inhibit H. pylori growth
in the stomach;60 (2) H. pylori might be eradicated upon
antibiotic treatment, both because antibiotics are commonly
used during the initial treatment periods, and because
antibiotic concentrations are higher in patients with renal
failure; (3) Patients receiving dialysis have higher levels of
proinflammatory cytokines, including interleukin-1b, -6, -8,
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Figure 2 | Changes in H. pylori infection rate in 1997, 1999,
and 2001 among total patients, CGN patients, and patients
with diabetes and others, and among different treatment
period groups. (a) The H. pylori infection rate was gradually
decreased irrespective of age, sex, and basement diseases
according to chronic dialysis treatment. H. pylori infection in
patients with diabetic nephropathy was significantly higher than
that in the CGN group. *Po0.05 (vs CGN and others groups).
Changes in H. pylori infection rate in 1997, 1999, and 2001 among
different treatment period groups. (b) The H. pylori infection rate
was significantly decreased according to chronic dialysis
treatment in patients with a treatment period of less than 4 years.
*Po0.05 (vs infection rate in 1997).
Table 5 | The change of the prevalence of H. pylori infection in
dialysis patients in a follow-up survey
Year Total CGN Diabetic nephritis Others
1997 1999 2001 n % n % n % n %
+ + + 179 68.3 129 72.1 36 58.0 14 66.7
+   41 15.6 25 14.0 15 24.2 1 4.7
+ +  25 9.5 13 7.3 6 9.7 6 28.6
+  + 2 0.8 2 1.1 0 0.0 0 0.0
   229 176 31 22
CGN, chronic glomerulonephritis; +, H. pylori infection positive; , H. pylori infection
negative.
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and tumor necrosis factor, from activated inflammatory cells
infiltrating the gastric mucosa.61 As a result, gastric atrophy
progresses, accompanied by increased pH, and finally
H. pylori are not able to live in gastric mucosa.62 In this
study, there was no significant difference in the prevalence of
H. pylori infection between patients with normal renal
function and patients receiving less than 1 year of dialysis
treatment. Therefore, urea concentration and antibiotic usage
are unlikely contributors to decrease the prevalence of
infection. One possible explanation for decreased H. pylori
prevalence is severe inflammation resulting from dialysis, and
progression to gastric atrophy. However, further studies to
investigate the histopathology of gastric inflammation and
atrophy are needed.
Dialysis patients may have a higher risk of gastric mucosal
damages compared with individuals with normal renal
function by systemic and/or local chronic circulatory
failure,63,64 hypergastrinemia,42 high ammonia levels,26 and
enhanced inflammation. Moreover, most dialysis patients
also receive anticoagulant drugs for hypertension and brain
infarction and/or heparin treatment. Therefore, patients
often incurred massive hemorrhage from either PUs or
gastric erosions. Importantly, we found that approximately
half of the dialysis patients with duodenal ulcer were H. pylori
negative although it is the consensus that most of the
duodenal ulcer patients are infected with H. pylori. In
addition, 15.2% (22 of 145) of H. pylori-negative patients still
developed severe gastroduodenal diseases, whereas none of
H. pylori-negative patients with normal renal function (0 of
9) developed severe gastroduodenal diseases. Sotoudehma-
nesh et al.10 also reported that H. pylori-negative dialysis
patients frequently revealed any erosions in stomach and/or
duodenum. These data indicate that not only H. pylori-
positive dialysis patients, but also H. pylori-negative dialysis
patients should receive endoscopic examination to prevent
potentially destructive gastrointestinal events.
In general, gastroduodenal symptoms are one of major
triggers to find out PU and neoplastic diseases in healthy
individuals. However, long-term dialysis patients often report
decreased sensory disturbance, and in the present study the
gastrointestinal symptoms of dialysis patients had no
association with endoscopically monitored gastrointestinal
diseases, which is in agreement with a previous report.57
Gastrointestinal symptoms in dialysis patients might be
caused not only by H. pylori infection, but also by high urea
levels, decline of gastrointestinal motility, and amyloid
protein deposition. In the present study, there were no
significant differences of the prevalence of each disease
between dialysis patients with and without gastroduodenal
symptoms irrespective of H. pylori infection (Table 4).
Dialysis patients may frequently develop PUs and erosion
without gastrointestinal symptoms, and therefore, patients
receiving dialysis irrespective to gastroduodenal symptoms
should undergo endoscopic evaluation.
One important question is whether H. pylori eradication
therapies are necessary for H. pylori-infected dialysis patients.
The data that more than one-third of the patients receiving
equal or less than 4 years of dialysis treatment had naturally
cured H. pylori infection, and that approximately half of the
dialysis patients with duodenal ulcer were H. pylori negative
indicate that the eradication therapy might be meaningless.
However, we showed that the frequency of PU in patients
receiving dialysis treatment equal or more than 10 years was
significantly higher in H. pylori-infected patients than in
uninfected patients and most ulcers in uninfected patients were
healing to the red scar stage, and active ulcers were rare. We
therefore recommend receiving eradication therapies for H.
pylori-infected dialysis patients, especially for patients receiving
dialysis treatment for long time (for example, 5 years or more)
where the chance of natural eradication becomes rare.
We also demonstrated that the prevalence of H pylori
infection in diabetic nephropathy patients was significantly
higher than in the CGN group. Although the data on the
prevalence of H. pylori infection in patients with type 2
diabetes remain contradictory,65,66 a higher infection rate
may be present due to an impaired immune system.67
However, in the present study, patients with diabetes showed
a decreased infection rate after the start of dialysis; therefore
immunosuppression observed in diabetic patients should be
considered independent of H. pylori infection.
In conclusion, we considered that although the prevalence
of H. pylori in Japanese patients receiving dialysis decreased
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Figure 3 | Four years’ follow-up of anti-H. pylori IgG antibody. All patients receiving dialysis (a) and patients with dialysis period
of less than 4 years (b). In all patients receiving dialysis and patients with a treatment period of less than 4 years, the median
anti-H. pylori IgG antibody level in 1997 was significantly higher than in 1999 and 2001.
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in about 60% of patients within the first 4 years of dialysis,
long-term dialysis patients irrespective of gastric symptoms
and H. pylori infection should receive endoscopic check-ups
and essential medication of acid-inhibitory drugs (for
example, proton pomp inhibitors) to reduce the chance of
developing severe gastroduodenal diseases. Moreover, we
recommend receiving eradication therapies for H. pylori-
infected dialysis patients, especially for patients receiving
dialysis for 5 years or more where the chance of natural
eradication becomes rare. The clinical protocol for a detailed
endoscopic check-up and eradication therapy for dialysis
patients should be evaluated in future studies.
MATERIALS AND METHODS
Patients
A total of 539 patients receiving chronic dialysis and 400 patients with
normal renal function were enrolled in this study. The criteria for control
patients were plasma creatinine levels less than 1.2 mg/100 ml and BUN
levels less than 25 mg/100 ml. We administered a questionnaire regarding
the severity of common gastrointestinal symptoms including dyspepsia,
vomiting, nausea, epigastralgia, and heartburn. The dialysis patients were
asked to rank the severity of the symptoms from 1 to 5 based on the
frequencies of the symptoms (1, asymptomatic; 2, mild symptoms: 1–3
days a month; 3, moderate symptoms: 1–3 days a week; 4, severe
symptoms: 4–6 days a week; and 5, very severe symptoms: everyday). No
patients enrolled in the study received previous treatment for H. pylori
infection. The research design was approved by the ethics committee and
informed consent was obtained from all patients.
H. pylori infection criteria and follow-up of anti-H. pylori IgG
antibody by ELISA
In all 539 dialysis patients and 400 patients with normal renal function
enrolled in this study, H. pylori status was determined using a serum
enzyme-linked immunosorbent assay (ELISA) test (Eiken Chemical,
Tokyo, Japan) at the beginning of the study (1997). In addition, in 478
patients receiving chronic dialysis, follow-up ELISA test was also
performed 2 and 4 years after (1999 and 2001). A positive reaction was
considered 420 U/ml. When were 15–20 U/ml (borderline), the ELISA
test was repeated within 1 month. If the titer was still within 15–20 U/ml,
H. pylori infection was evaluated by 13C-urea breath test, culture,
and/or rapid urease test. When at least one of alternative tests was
positive, we judged the patients as H. pylori infection positive.
Endoscopic check-up
Information about gastroduodenal diseases was obtained from 299
patients receiving hemodialysis and all 400 patients with normal
renal function. Endoscopy was performed for patients receiving
chronic dialysis between May 1996 and April 1998 and for patients
with normal renal function between January 1996 and April 1997.
H. pylori-related diseases were diagnosed by endoscopy and
histopathology. Endoscopic findings were divided into five diseases:
simple gastritis or normal appearing mucosa without ulcer and
malignancy (gastritis), gastric ulcer, duodenal ulcer, gastric cancer,
and others. PUs with red scars were categorized as ulcers, but those
with white scars (completely cured) were considered simple gastritis.
Data analysis
Statistical differences in demographic characteristics (mean age,
men/women), prevalence of H. pylori, frequency of gastrointestinal
diseases, and treatment period among different disease groups were
determined by one-way analysis of variance or the w2-test. To
determine whether anti-H. pylori IgG levels differed between the
three time points, Wilcoxon’s signed-rank test was used when
significant differences were observed by Friedmann’s test. Statisti-
cally significant differences in symptom scores were determined
using the Mann–Whitney U-test when significant differences were
observed by the Kruskal–Wallis test. Parametric data are presented as
mean±s.d., and nonparametric data as median (25–75% quartiles).
All P-values were two sided, and P-values o0.05 were considered
statistically significant.
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